
    
      Data from dose-escalated Phase I trials indicate that CPI-613 is safe and effective against
      metastatic pancreatic cancer (Lee et al. 2012; Retter et al. 2012). Accordingly, this Phase
      II trial is conducted to assess the safety and efficacy of CPI-613 in patients with
      metastatic pancreatic cancer.

      Primary Outcome Measure:

      - Overall Survival (OS)

      Secondary Outcome Measures:

        -  Changes in CA 19-9

        -  Quality of Life (QOL) assessment

        -  Progression-Free Survival (PFS)

        -  Safety
    
  